Literature DB >> 29427124

Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis-Prognostic and Predictive Factors.

José Manuel Cameselle-Teijeiro1, José Antonio Mato Mato2, Ovidio Fernández Calvo2, Jesús García Mata3.   

Abstract

Neuroendocrine tumors (NETs) belong to a heterogeneous family of rare tumors with very broad and complex clinical behavior. Due to their heterogeneity, the lack of specific symptoms and the absence of sensitive methods for early detection, patients are usually diagnosed when the disease is in an advanced state for which curative treatments are scarce. In most cases, these few treatments try to prolong the survival of patients, maintaining the quality of life. The identification of biomarkers could help to improve early diagnosis and to choose the most suitable therapeutic strategy. This paper provides a review of the current histopathological diagnostic approaches for lung NET subtypes, including the predictive and prognostic factors, to help in the early diagnosis of this disease.

Entities:  

Mesh:

Year:  2018        PMID: 29427124     DOI: 10.1007/s40291-018-0315-2

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  77 in total

1.  Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report.

Authors:  Guido Rindi; C Bordi; S La Rosa; E Solcia; Gianfranco Delle Fave
Journal:  Dig Liver Dis       Date:  2011-03       Impact factor: 4.088

2.  Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.

Authors:  Julie Hallet; Calvin How Lim Law; Moises Cukier; Refik Saskin; Ning Liu; Simron Singh
Journal:  Cancer       Date:  2014-10-13       Impact factor: 6.860

3.  Two different types of carcinoid tumors of the lung: immunohistochemical and ultrastructural investigation and their histogenetic consideration.

Authors:  Kyung-Whan Min
Journal:  Ultrastruct Pathol       Date:  2013-02       Impact factor: 1.094

4.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

5.  Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.

Authors:  Byung Woo Jhun; Kyung-Jong Lee; Kyeongman Jeon; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Joon Young Choi; Kyung Soo Lee; Joungho Han; Sang-Won Um
Journal:  Lung Cancer       Date:  2013-03-22       Impact factor: 5.705

6.  Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer.

Authors:  Fang Yang; Yina Gao; Jingshu Geng; Di Qu; Qiuyue Han; Jiping Qi; Gongyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

Review 7.  Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.

Authors:  Giuseppe Pelosi; Guido Rindi; William D Travis; Mauro Papotti
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

8.  Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors.

Authors:  S Lantuejoul; D Moro; R J Michalides; C Brambilla; E Brambilla
Journal:  Am J Surg Pathol       Date:  1998-10       Impact factor: 6.394

9.  18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.

Authors:  Tina Binderup; Ulrich Knigge; Annika Loft; Birgitte Federspiel; Andreas Kjaer
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

10.  Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.

Authors:  Yuki Matsumura; Shigeki Umemura; Genichiro Ishii; Koji Tsuta; Shingo Matsumoto; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Yuichiro Ohe; Hiroyuki Suzuki; Atsushi Ochiai; Koichi Goto; Kanji Nagai; Katsuya Tsuchihara
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-20       Impact factor: 4.553

View more
  3 in total

1.  Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells.

Authors:  Kristina B V Døssing; Christina Kjær; Jonas Vikeså; Tina Binderup; Ulrich Knigge; Michael D Culler; Andreas Kjær; Birgitte Federspiel; Lennart Friis-Hansen
Journal:  Genes (Basel)       Date:  2018-07-04       Impact factor: 4.096

2.  SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.

Authors:  Lu Yu; Yuting Dong; Jin Xue; Sanpeng Xu; Guoping Wang; Dong Kuang; Yaqi Duan
Journal:  Diagn Pathol       Date:  2022-01-07       Impact factor: 2.644

3.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.